A Phase 2A Open-label Trial to Assess the Safety of ZIMURA (Anti-C5) Administered in Combination With LUCENTIS 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Avacincaptad pegol (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; First in man
- Sponsors OphthoTech Corporation
- 14 Nov 2018 Status changed from active, no longer recruiting to completed.
- 12 Nov 2018 Results presented in an OphthoTech Corporation media media release
- 04 Oct 2018 According to an OphthoTech Corporation media release, top-line data from the trial is expected before the end of the year.